Elevance Health shares are trading lower after Argus Research downgraded the stock from Buy to Hold and multiple firms cut their respective price targets.
Portfolio Pulse from Benzinga Newsdesk
Elevance Health's stock is experiencing a decline following a downgrade by Argus Research from Buy to Hold, along with several firms reducing their price targets for the company.
October 18, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Elevance Health's stock is trading lower due to a downgrade by Argus Research from Buy to Hold, and several firms have also reduced their price targets.
The downgrade from Argus Research and the reduction in price targets by multiple firms are likely to negatively impact investor sentiment, leading to a short-term decline in Elevance Health's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100